CRISPR Therapeutics (CRSP) reported Tuesday a Q4 loss of $0.44 per diluted share, swinging from earnings of $1.10 a year earlier.

Analysts polled by FactSet expected a loss of $1.20.

Total revenue for the quarter ended Dec. 31 was $35.7 million, down from 201.2 million a year earlier.

Analysts surveyed by FactSet expected $8.1 million.

As of Dec. 31, the company had about $1.90 billion in cash, cash equivalents, and marketable securities, compared with about $1.7 billion a year earlier.